Proper management of COVID-19 mandates better understanding of disease pathogenesis.
The sudden clinical deterioration 7–8 days after initial symptom onset suggests that severe …

Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …

Background Anakinra might improve the prognosis of patients with moderate to severe
COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ support). …

As of April 1, 2020, 885,689 cases of infections by the novel coronavirus SARS-CoV-2 (COVID-19)
have been recorded worldwide; 44,217 of them have died (https://www. worldometers…

Background: It was studied if early suPAR-guided anakinra treatment can prevent severe
respiratory failure (SRF) of COVID-19. Methods: A total of 130 patients with suPAR ≥6 ng/ml …

In a recent study of our group with the acronym ACTIVATE, Bacillus Calmete-Guérin (BCG)
vaccination reduced the occurrence of new infections compared to placebo vaccination in the …

Background Estimates of demographic metrics are crucial to assess levels and trends of
population health outcomes. The profound impact of the COVID-19 pandemic on populations …

Background A subanalysis of a randomized clinical trial indicated sepsis survival benefit
from interleukin (IL)-1 blockade in patients with features of the macrophage activation-like …

Despite the rapid development of efficient and safe vaccines against COVID-19, the need to
confine the pandemic and treat infected individuals on an outpatient basis has led to the …

Background Disorders affecting the nervous system are diverse and include neurodevelopmental
disorders, late-life neurodegeneration, and newly emergent conditions, such as …